Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pra Health (PRAH)

Pra Health (PRAH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,704,781
  • Shares Outstanding, K 64,795
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 197,040 K
  • 60-Month Beta 1.33
  • Price/Sales 3.42
  • Price/Cash Flow 27.57
  • Price/Book 6.88
Trade PRAH with:
  • Price/Earnings ttm 38.71
  • Earnings Per Share ttm 4.34
  • Most Recent Earnings 1.35 on 04/28/21
  • Next Earnings Date 08/05/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 11.79%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 1.24
  • Number of Estimates 3
  • High Estimate 1.26
  • Low Estimate 1.22
  • Prior Year 0.69
  • Growth Rate Est. (year over year) +79.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.28 +0.57%
on 06/30/21
172.43 -4.19%
on 06/01/21
-5.71 (-3.34%)
since 05/28/21
3-Month
151.77 +8.86%
on 04/01/21
175.95 -6.10%
on 05/25/21
+11.45 (+7.45%)
since 03/30/21
52-Week
93.00 +77.65%
on 07/14/20
175.95 -6.10%
on 05/25/21
+67.92 (+69.81%)
since 06/30/20

Most Recent Stories

More News
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation

ICON plc, (NASDAQ: ICLR) ("ICON") today announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees across...

PRAH : 165.21 (-1.67%)
ICLR : 243.27 (+1.11%)
DT Midstream Set to Join S&P MidCap 400

/PRNewswire/ -- DT Midstream Inc. (NYSE: DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on . ICON plc (NASD: ICLR) is acquiring PRA Health Sciences...

DTM : 42.40 (-2.15%)
PRAH : 165.21 (-1.67%)
ICLR : 243.27 (+1.11%)
DTE : 117.32 (-0.69%)
SPGI : 428.72 (+1.22%)
Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research

Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.

MDRX : 17.08 (-0.87%)
ABC : 122.17 (-0.44%)
VEEV : 332.71 (+0.03%)
PRAH : 165.21 (-1.67%)
Veradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research Network

Veradigm(R), a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and PRA Health Sciences, Inc. (NASDAQ: PRAH), one of the...

PRAH : 165.21 (-1.67%)
MDRX : 17.08 (-0.87%)
ICON Announces Pricing of Senior Secured Notes

ICON plc (NASDAQ: ICLR) ("ICON") announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. ("PRA") pursuant to which Indigo Merger Sub, Inc., a wholly owned subsidiary...

PRAH : 165.21 (-1.67%)
ICLR : 243.27 (+1.11%)
ICON Shareholders Vote in Favour of All Resolutions at its Extraordinary General Meeting

ICON plc (NASDAQ: ICLR) ("ICON"), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health...

PRAH : 165.21 (-1.67%)
ICLR : 243.27 (+1.11%)
ICON Announces Private Offering of Senior Secured Notes

ICON plc (NASDAQ: ICLR) ("ICON") announced today in connection with the proposed acquisition by ICON of PRA Health Sciences, Inc. ("PRA") pursuant to which Indigo Merger Sub, Inc., a wholly owned subsidiary...

PRAH : 165.21 (-1.67%)
ICLR : 243.27 (+1.11%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PRAH, SVBI, ATH, MRLN, MDCA; Shareholders are Encouraged to Contact the Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

PRAH : 165.21 (-1.67%)
SVBI : 12.24 (+1.24%)
ATH : 64.62 (-0.98%)
MRLN : 22.56 (-0.57%)
MDCA : 5.61 (-1.75%)
Here's Why You Should Retain PRA Health (PRAH) Stock for Now

Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

ILMN : 495.75 (+0.84%)
AMED : 260.62 (+2.02%)
DVA : 120.25 (+1.04%)
PRAH : 165.21 (-1.67%)
Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors

Strengthening Board of Directors with Expertise in Innovative Product Launches

TMDX : 28.52 (-2.33%)
PRAH : 165.21 (-1.67%)
AVXL : 17.95 (-1.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology...

See More

Key Turning Points

3rd Resistance Point 172.37
2nd Resistance Point 170.56
1st Resistance Point 167.89
Last Price 165.21
1st Support Level 163.41
2nd Support Level 161.60
3rd Support Level 158.93

See More

52-Week High 175.95
Last Price 165.21
Fibonacci 61.8% 144.26
Fibonacci 50% 134.48
Fibonacci 38.2% 124.69
52-Week Low 93.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar